Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial

IMPORTANCE: The morbidity and mortality associated with COVID-19 remain high despite advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit the interleukin 6/JAK2 pathway is still being elucidated. OBJECTIVE: To evaluate the efficacy and safety of the oral JAK2/I...

Descripción completa

Detalles Bibliográficos
Autores principales: Cafardi, John, Miller, Carole, Terebelo, Howard, Tewell, Chad, Benzaquen, Sadia, Park, David, Egan, Pamela, Lebovic, Daniel, Pettit, Kristen, Whitman, Eric, Tremblay, Douglas, Feld, Jonathan, Buckley, Sarah, Roman-Torres, Karisse, Smith, Jennifer, Craig, Adam, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855296/
https://www.ncbi.nlm.nih.gov/pubmed/36469321
http://dx.doi.org/10.1001/jamanetworkopen.2022.42918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855296/
https://www.ncbi.nlm.nih.gov/pubmed/36469321
http://dx.doi.org/10.1001/jamanetworkopen.2022.42918

Ejemplares similares